These studies demonstrated that AN0128 was well tolerated at the site of application and indicated that further study was warranted.
“While atopic dermatitis is fundamentally a disease of the immune system, one of the primary triggers for the disease is the presence of Staph aureus on the skin,” said Dr Karl Beutner, chief medical officer at Anacor. “Therefore, physicians often treat atopic dermatitis with a combination of antibiotics and anti-inflammatories. AN0128 holds the promise of treating both components of the disease with a single compound.”
Anacor scientists and collaborators presented six posters detailing the preclinical and clinical studies of AN0128 at the American Academy of Dermatology’s annual meeting.
Anacor is currently enrolling patients in a double-blind, placebo-controlled phase II study of AN0128 for the treatment of atopic dermatitis. The study will evaluate 100 patients at multiple US centers.